Capital Counsel’s Ionis Pharmaceuticals IONS Stock Holding History

Capital Counsel’s Portfolio IONS Stock Details IONS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$3.72M	Sell	49,580 -25	-0.1%	-$1.97K	0.16%	21
2025 Q4	$3.92M	Hold	49,605	–	–	0.15%	23
2025 Q3	$3.25M	Sell	49,605 -600	-1%	-$29.3K	0.12%	24
2025 Q2	$1.98M	Buy	50,205 +13,125	+35%	+$430K	0.08%	25
2025 Q1	$1.12M	Hold	37,080	–	–	0.05%	30
2024 Q4	$1.3M	Hold	37,080	–	–	0.06%	29
2024 Q3	$1.49M	Hold	37,080	–	–	0.06%	28
2024 Q2	$1.77M	Sell	37,080 -2,500	-6%	-$103K	0.08%	26
2024 Q1	$1.72M	Sell	39,580 -500	-1%	-$23.8K	0.08%	25
2023 Q4	$2.03M	Sell	40,080 -150	-0.4%	-$7.18K	0.1%	24
2023 Q3	$1.82M	Hold	40,230	–	–	0.1%	25
2023 Q2	$1.65M	Hold	40,230	–	–	0.09%	26
2023 Q1	$1.44M	Hold	40,230	–	–	0.08%	27
2022 Q4	$1.52M	Hold	40,230	–	–	0.1%	24
2022 Q3	$1.78M	Sell	40,230 -780	-2%	-$32.9K	0.12%	22
2022 Q2	$1.52M	Hold	41,010	–	–	0.09%	24
2022 Q1	$1.52M	Buy	41,010 +430	+1%	+$14.1K	0.07%	27
2021 Q4	$1.24M	Hold	40,580	–	–	0.05%	30
2021 Q3	$1.36M	Hold	40,580	–	–	0.07%	28
2021 Q2	$1.62M	Sell	40,580 -1,500	-4%	-$58.8K	0.08%	27
2021 Q1	$1.89M	Hold	42,080	–	–	0.11%	24
2020 Q4	$2.38M	Hold	42,080	–	–	0.14%	20
2020 Q3	$2M	Buy	42,080 +2,700	+7%	+$150K	0.13%	21
2020 Q2	$2.32M	Hold	39,380	–	–	0.17%	21
2020 Q1	$1.86M	Hold	39,380	–	–	0.15%	23
2019 Q4	$2.38M	Hold	39,380	–	–	0.16%	26
2019 Q3	$2.36M	Hold	39,380	–	–	0.17%	25
2019 Q2	$2.53M	Sell	39,380 -5,000	-11%	-$353K	0.17%	26
2019 Q1	$3.6M	Buy	44,380 +1,000	+2%	+$64.5K	0.26%	25
2018 Q4	$2.35M	Hold	43,380	–	–	0.19%	25
2018 Q3	$2.24M	Hold	43,380	–	–	0.16%	29
2018 Q2	$1.81M	Buy	43,380 +1,000	+2%	+$44.3K	0.14%	27
2018 Q1	$1.87M	Buy	42,380 +1,100	+3%	+$55.9K	0.15%	27
2017 Q4	$2.08M	Hold	41,280	–	–	0.17%	28
2017 Q3	$2.09M	Hold	41,280	–	–	0.19%	27
2017 Q2	$2.1M	Buy	41,280 +3,250	+9%	+$151K	0.19%	27
2017 Q1	$1.53M	Buy	38,030 +500	+1%	+$22.5K	0.15%	31
2016 Q4	$1.79M	Hold	37,530	–	–	0.19%	29
2016 Q3	$1.38M	Buy	37,530 +9,000	+32%	+$282K	0.12%	30
2016 Q2	$664K	Buy	28,530 +10,100	+55%	+$326K	0.06%	35
2016 Q1	$746K	Buy	18,430 +430	+2%	+$17.5K	0.07%	34
2015 Q4	$1.11M	Buy	18,000 +5,000	+38%	+$270K	0.06%	53
2015 Q3	$525K	Hold	13,000	–	–	0.03%	70
2015 Q2	$748K	Hold	13,000	–	–	0.04%	66
2015 Q1	$828K	Hold	13,000	–	–	0.04%	63
2014 Q4	$803K	Hold	13,000	–	–	0.04%	67
2014 Q3	$505K	Buy	13,000 +1,000	+8%	+$35.4K	0.03%	78
2014 Q2	$413K	Buy	+12,000	New	+$378K	0.02%	87

Other funds holding IONS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital Counsel's IONS Position: Q1 2026 in Review

Capital Counsel reduced its Ionis Pharmaceuticals (IONS) stake by 0.05% in Q1 2026, selling an estimated $1.97K and leaving 49,580 shares worth $3.72M. The position accounts for 0.16% of the portfolio, ranked #21.

Capital Counsel first reported a position in IONS in Q2 2014 and has held it in 48 quarters since. The position peaked at $3.92M in Q4 2025. 493 funds tracked by Wall St. Rank hold IONS as of Q1 2026.

Capital Counsel held 49,580 shares of Ionis Pharmaceuticals worth $3.72M as of Q1 2026.
Capital Counsel sold 25 Ionis Pharmaceuticals shares in Q1 2026, an estimated $1.97K.
Ionis Pharmaceuticals made up 0.16% of Capital Counsel's portfolio in Q1 2026, its #21 holding.
Capital Counsel first reported a position in Ionis Pharmaceuticals in Q2 2014 and has held it in 48 quarters since.
Capital Counsel's Ionis Pharmaceuticals position peaked at $3.92M in Q4 2025.
493 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q1 2026.

Based on Capital Counsel's 13F filing for Q1 2026, filed 15 May 2026.